

COMPLETION OF SHARE PURCHASE PLAN

- IIQ completed its share purchase plan with applications totalling A\$0.7m million accepted
- Total capital raised of A\$10.2 million under both the SPP and recent placement (A\$9.5 million) to institutional and sophisticated investors
- Funds will be used to accelerate clinical validation and LDT commercialisation of the EXO-OC™ ovarian cancer test and preclinical development of the exosome therapeutic program for solid tumours

INOVIQ Limited (ASX:IIQ) (**INOVIQ** or the **Company**) is pleased to announce the completion of the share purchase plan (**SPP**) announced on 13 October 2025, with applications accepted for A\$0.7 million. The Company was seeking to raise up to A\$2 million through the SPP.

The SPP provided eligible shareholders with the opportunity to purchase new shares on the same terms as the recently completed placement to institutional and sophisticated investors (**Placement**) at \$0.35 per share. The Placement was completed on 17 October 2025 with a total of A\$9.5 million raised and 27,142,856 fully paid ordinary shares (**Shares**) issued.

Full details of the SPP were set out in the Company's SPP Offer Booklet which was released to the ASX on 17 October 2025.

A total of 1,999,800 fully paid ordinary shares (**SPP Shares**), will be issued on Wednesday, 5 November 2025 (holding statements are expected to be dispatched Thursday 6 November 2025).

IIQ expects the Shares issued under the SPP to commence trading on a normal settlement basis on or about Wednesday, 5 November 2025.

Authorised for release by Company Secretary, Mark Edwards.

FURTHER INFORMATION

Dr Leearne Hinch
Chief Executive Officer
E lhinch@inoviq.com
M +61 400 414 416

David Williams
Chairman
E dwilliams@kidder.com.au
M +61 414 383 593

ABOUT INOVIQ LTD

INOVIQ Ltd (ASX: IIQ) is a leader in exosome technology advancing next-generation diagnostics and therapeutics to transform cancer care. Our product portfolio includes commercial-stage exosome isolation products, clinical-stage diagnostics for ovarian and breast cancers, and a cutting-edge preclinical CAR-exosome therapeutic program for solid tumours. INOVIQ is shaping the future of cancer detection and treatment to improve patient outcomes. For more information on INOVIQ, visit www.inoviq.com.